FRANKFURT (dpa-AFX) – A skeptical study by the bank HSBC with the emphasis on a continued difficult business environment weighed on the shares of the dialysis group FMC (Fresenius Medical Care (FMC) St) on Tuesday. As the last in the MDAX, they fell by 2.27 percent to EUR 43.57. They initially fell below the important support around 44 euros, which had recently offered support several times. The closing price is therefore important.
In a study, analyst Sezgi Oezener raised the price target for the shares of the Fresenius (Fresenius SECo) subsidiary from EUR 33 to EUR 38, but still sees room for improvement and confirmed her “Reduce” recommendation.
The tightening of the FMC group structure is having a positive impact on productivity and agility, but the environment remains difficult, the expert explained. Looking at the US, the increase in fee reimbursements for dialysis treatments is unlikely to be sufficient to compensate for the increased costs due to inflation. Therefore, dialysis providers would find it difficult to increase their profitability./mis/jha/
Selected leverage products on Fresenius Medical Care (FMC) St.
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired lever and we will show you suitable open-end products at Fresenius Medical Care (FMC) St.
Leverage must be between 2 and 20